Since May 2014, Mark Kaufmann has been the chief financial officer of Ardelyx, Inc. after joining the company as chief business officer in August 2011. Mark has over 20 years of experience in the biopharmaceutical industry in both the U.S. and Canada in business and corporate development roles. At Ardelyx, he was instrumental in over $1B of deals with pharmaceutical companies as well as the Company’s initial public offering and several subsequent financings. Prior to joining Ardelyx, Mark was president and chief executive officer of Allostera Pharma Inc., a preclinical company focused on autoimmune diseases, and before that was president and chief executive officer of Celmed BioSciences, Inc. Mark started his career as director of strategic planning and investor relations at MedImmune in 1994. Mark received his B.A. in biochemical sciences from Harvard University and his MBA from the University of Michigan School of Business.